69_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Selected_NNP Financial_NNP Data_NNP Our_PRP$ audited_JJ historical_JJ consolidated_JJ financial_JJ statements_NNS are_VBP presented_VBN in_IN British_JJ pounds_NNS sterling_NN and_CC are_VBP prepared_VBN in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
UK_NNP GAAP_NNP differs_VBZ in_IN certain_JJ respects_NNS from_IN US_NNP GAAP_NNP ._.
A_DT reconciliation_NN of_IN certain_JJ amounts_NNS from_IN UK_NNP GAAP_NNP to_TO US_NNP GAAP_NNP ,_, as_RB well_RB as_IN a_DT summary_NN of_IN principal_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP applicable_JJ to_TO us_PRP ,_, are_VBP presented_VBN in_IN note_NN 27_CD to_TO our_PRP$ audited_JJ historical_JJ consolidated_JJ financial_JJ statements_NNS included_VBD elsewhere_RB in_IN this_DT annual_JJ report_NN ._.
The_DT following_VBG summary_NN financial_JJ data_NNS should_MD be_VB read_VBN in_IN conjunction_NN with_IN Operating_NN and_CC Financial_NNP Review_NNP and_CC Prospects_NNP and_CC our_PRP$ historical_JJ consolidated_JJ financial_JJ statements_NNS ,_, including_VBG the_DT notes_NNS thereto_RB ._.
The_DT summary_NN statement_NN of_IN income_NN data_NNS set_VBN forth_RB below_IN for_IN the_DT fiscal_JJ years_NNS ended_VBN 30_CD September_NNP 2002_CD ,_, 2001_CD ,_, 2000_CD ,_, 1999_CD and_CC 1998_CD ,_, and_CC the_DT consolidated_JJ balance_NN sheet_NN data_NNS at_IN 30_CD September_NNP 2002_CD ,_, 2001_CD ,_, 2000_CD ,_, 1999_CD and_CC 1998_CD have_VBP been_VBN derived_VBN from_IN our_PRP$ audited_JJ historical_JJ consolidated_JJ financial_JJ statements_NNS ,_, but_CC do_VBP not_RB ,_, however_RB ,_, constitute_VBP our_PRP$ statutory_JJ accounts_NNS within_IN the_DT meaning_NN of_IN Section_NN 240_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD in_IN the_DT United_NNP Kingdom_NNP ._.
ii_FW Under_IN UK_NNP GAAP_NNP ,_, potentially_RB dilutive_JJ issuable_JJ shares_NNS are_VBP only_RB included_VBN in_IN the_DT calculation_NN of_IN fully_RB diluted_VBN earnings_NNS per_IN share_NN if_IN their_PRP$ issue_NN would_MD decrease_VB net_JJ profit_NN per_IN share_NN or_CC increase_NN net_JJ loss_NN per_IN share_NN ._.
Since_IN the_DT Group_NNP has_VBZ reported_VBN losses_NNS ,_, its_PRP$ basic_JJ and_CC fully_RB diluted_JJ loss_NN per_IN share_NN are_VBP therefore_RB equal_JJ ._.
